Sort   by:  
 Page size 
TranscriptomicsEGI-1 cell line treated with Saracatinib vs EGI-1 cell line untreated; EGI-1 xenograft treated with Saracatinib vs EGI-1 untreated
Biliary tract carcinoma (BTC) has a poor prognosis due to limited treatment options. There is therefore urgent need to identify new targets and to design innovative therapeutic approaches. Among potential candidate molecules, we evaluated the non-receptor tyrosine kinase Src, observing promising ant...
ORGANISM(S): Homo sapiens 
2012-08-02 | E-GEOD-36622 | biostudies-arrayexpress
TranscriptomicsHER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib
HER2 targeting with trastuzumab has changed the prognosis of breast cancer patients carrying amplification and/or overexpression of this oncogene. Despite this progress, however, resistance to trastuzumab occurs in the vast majority of patients. Newer anti-HER2 therapies, like the dual tyrosine-kina...
ORGANISM(S): Homo sapiens 
2010-12-15 | E-GEOD-17630 | biostudies-arrayexpress
TranscriptomicsExpression data from untreated and ATP treated AML blasts
In the present study, we investigated whether, and to what extent, P2Rs and their ligands are involved in the regulation of AML cells. Our findings show that AML blasts express several receptors belonging to the P2X and P2Y family. Although different samples respond differently to ATP and UTP stimul...
ORGANISM(S): Homo sapiens 
2012-02-25 | E-GEOD-30903 | biostudies-arrayexpress
Genomicsena-DATASET-JHUSM-28-09-2015-22:11:53:244-560 - samples
Description not provided
EGAD00001001628 | EGA
Genomicsena-DATASET-JHUSM-16-11-2015-19:53:19:325-4 - samples
Description not provided
EGAD00001001674 | EGA
GenomicsThe Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer world-wide with 1.2 million patients diagnosed yearly. In late stage CRC, the most commonly used targeted therapies are monoclonal antibodies cetuximab and panitumumab, which inactivate EGFR. Recent studies have identified alterations in KRAS...
EGAS00001001305 | EGA
GenomicsDAC for the study of response to EGFR Blockade in Colorectal Cancer
Data Access Committee EGAC00001000360
EGAC00001000360 | EGA
TranscriptomicsGene profiling, mutations and expression of epidermal growth factor receptor in androgen-dependent prostate cancer
We analyzed mutations in Epidermal Growth Factor Receptor (EGFR) Tyrosine kinase (TK) domain, EGFR expression and gene profiling in prostate carcinoma (PC) in order to find out molecular prognostic markers and supply a proof for EGFR targeted therapies. 100 glyofixx-fixed, paraffin-embedded PC spec...
ORGANISM(S): Homo sapiens 
2011-06-30 | E-GEOD-16120 | biostudies-arrayexpress
Sort   by:  
 Page size